Methods: 2400 Participants over 50 were randomized into intervention and control groups. Consent was obtained post-randomization. Consenting participants in the intervention group were given a pill containing aspirin, atorvastatin, hydrochlorothiazide, and valsartan (polypill). Participants were followed for 5 years. pNASH was diagnosed by ultrasonography and elevated liver enzymes. The primary outcome was MCVE. ClinicalTrials.gov: NCT01245608.
Results: Among the originally randomized population, 138/1249 in the intervention group (11.0%) and 137/1017 controls (13.5%) had MCVE during the 5-year follow-up (unadjusted risk ratio [RR] 0.83, 95% confidence interval [CI] 0.66-1.03). Of the 1508 participants who consented to additional measurements and treatment, 63/787 (8.0%) intervention group participants and 86/721 (11.9%) controls had MCVE (adjusted RR 0.61, 95% CI 0.44-0.83). Although the adjusted relative risk of MCVE in participants with pNASH (0.35, 95% CI 0.17-0.74) was under half that for participants without pNASH (0.73, 95% CI 0.49-1.00), the difference did not reach statistical significance. There was no change in liver enzymes in participants taking polypill but among those with pNASH, there was a significant decrease after 60 months of follow-up (intragroup -12.0 IU/L, 95% CI -14.2 to -9.6).
Conclusion: Among patients consenting to receive fixed-dose combination therapy, polypill is safe and effective for prevention of MCVE, even among participants with fatty liver and increased liver enzymes.
- cardiovascular diseases
- primary prevention
- secondary prevention